YD-277

  Cat. No.:  DC11822  
Chemical Structure
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
A novel small molecule KLF5 inhibitor derived from ML264, demonstrates >10-fold enhanced efficacy in multiple cancer cell lines with IC50 of 1.5-10 uM.
Cas No.:
Chemical Name: tert-butyl (E)-4-(2-(3-(3-chlorophenyl)acrylamido)-N-methylacetamido)piperidine-1-carboxylate
Synonyms: YD 277;YD277
SMILES: N(C(OC(C)(C)C)=O)1CCC(N(C)C(=O)CNC(=O)/C=C/C2=CC=CC(Cl)=C2)CC1
Formula: C22H30ClN3O4
M.Wt: 435.949
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: A novel small molecule KLF5 inhibitor derived from ML264, demonstrates >10-fold enhanced efficacy in multiple cancer cell lines with IC50 of 1.5-10 uM; decreases cancer cell viability in a KLF5-independent manner, induces G1 cell cycle arrest and promotes apoptosis through activating IRE1α in MDA-MB-231 and MDA-MB-468 cells; significantly inhibits the growth of MDA-MB-231 tumor xenografts in nude mice.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC11822 YD-277 A novel small molecule KLF5 inhibitor derived from ML264, demonstrates >10-fold enhanced efficacy in multiple cancer cell lines with IC50 of 1.5-10 uM.
X